Literature DB >> 15879094

CD40 ligation activates murine macrophages via an IFN-gamma-dependent mechanism resulting in tumor cell destruction in vitro.

Ilia N Buhtoiarov1, Hillary Lum, Gideon Berke, Donna M Paulnock, Paul M Sondel, Alexander L Rakhmilevich.   

Abstract

We have shown previously that agonistic anti-CD40 mAb induced T cell-independent antitumor effects in vivo. In this study, we investigated mechanisms of macrophage activation with anti-CD40 mAb treatment, assessed by the antitumor action of macrophages in vitro. Intraperitoneal injection of anti-CD40 mAb into C57BL/6 mice resulted in activation of peritoneal macrophages capable of suppressing B16 melanoma cell proliferation in vitro, an effect that was greatly enhanced by LPS and observed against several murine and human tumor cell lines. Anti-CD40 mAb also primed macrophages in vitro to mediate cytostatic effects in the presence of LPS. The tumoristatic effect of CD40 ligation-activated macrophages was associated with apoptosis and killing of tumor cells. Activation of macrophages by anti-CD40 mAb required endogenous IFN-gamma because priming of macrophages by anti-CD40 mAb was abrogated in the presence of anti-IFN-gamma mAb, as well as in IFN-gamma-knockout mice. Macrophages obtained either from C57BL/6 mice depleted of T and NK cells by Ab treatment, or from scid/beige mice, were still activated by anti-CD40 mAb to mediate cytostatic activity. These results argued against the role of NK and T cells as the sole source of exogenous IFN-gamma for macrophage activation and suggested that anti-CD40 mAb-activated macrophages could produce IFN-gamma. We confirmed this hypothesis by detecting intracytoplasmic IFN-gamma in macrophages activated with anti-CD40 mAb in vivo or in vitro. IFN-gamma production by macrophages was dependent on IL-12. Taken together, the results show that murine macrophages are activated directly by anti-CD40 mAb to secrete IFN-gamma and mediate tumor cell destruction.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15879094     DOI: 10.4049/jimmunol.174.10.6013

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  50 in total

1.  Anti-tumour synergy of cytotoxic chemotherapy and anti-CD40 plus CpG-ODN immunotherapy through repolarization of tumour-associated macrophages.

Authors:  Ilia N Buhtoiarov; Paul M Sondel; Jon M Wigginton; Tatiana N Buhtoiarova; Eric M Yanke; David A Mahvi; Alexander L Rakhmilevich
Journal:  Immunology       Date:  2010-10-13       Impact factor: 7.397

2.  Tumoricidal effects of activated macrophages in a mouse model of chronic lymphocytic leukemia.

Authors:  Qing-Li Wu; Ilia N Buhtoiarov; Paul M Sondel; Alexander L Rakhmilevich; Erik A Ranheim
Journal:  J Immunol       Date:  2009-06-01       Impact factor: 5.422

3.  Activation outcomes induced in naïve CD8 T-cells by macrophages primed via "phagocytic" and nonphagocytic pathways.

Authors:  Isabel María Olazabal; Noa Beatriz Martín-Cofreces; María Mittelbrunn; Gloria Martínez del Hoyo; Balbino Alarcón; Francisco Sánchez-Madrid
Journal:  Mol Biol Cell       Date:  2007-12-12       Impact factor: 4.138

4.  Antitumor effects of anti-CD40/CpG immunotherapy combined with gemcitabine or 5-fluorouracil chemotherapy in the B16 melanoma model.

Authors:  Xiaoyi Qu; Mildred A R Felder; Zulmarie Perez Horta; Paul M Sondel; Alexander L Rakhmilevich
Journal:  Int Immunopharmacol       Date:  2013-11-04       Impact factor: 4.932

5.  Tumoricidal Effects of Macrophage-Activating Immunotherapy in a Murine Model of Relapsed/Refractory Multiple Myeloma.

Authors:  Jeffrey Lee Jensen; Alexander Rakhmilevich; Erika Heninger; Aimee Teo Broman; Chelsea Hope; Funita Phan; Shigeki Miyamoto; Ioanna Maroulakou; Natalie Callander; Peiman Hematti; Marta Chesi; P Leif Bergsagel; Paul Sondel; Fotis Asimakopoulos
Journal:  Cancer Immunol Res       Date:  2015-05-04       Impact factor: 11.151

Review 6.  T-cell-independent antitumor effects of CD40 ligation.

Authors:  Alexander L Rakhmilevich; Kory L Alderson; Paul M Sondel
Journal:  Int Rev Immunol       Date:  2012-08       Impact factor: 5.311

Review 7.  Macrophages in multiple myeloma: emerging concepts and therapeutic implications.

Authors:  Fotis Asimakopoulos; Jaehyup Kim; Ryan A Denu; Chelsea Hope; Jeffrey L Jensen; Samuel J Ollar; Ellen Hebron; Claire Flanagan; Natalie Callander; Peiman Hematti
Journal:  Leuk Lymphoma       Date:  2013-04-11

Review 8.  CD40 immunotherapy for pancreatic cancer.

Authors:  Robert H Vonderheide; David L Bajor; Rafael Winograd; Rebecca A Evans; Lauren J Bayne; Gregory L Beatty
Journal:  Cancer Immunol Immunother       Date:  2013-04-16       Impact factor: 6.968

Review 9.  Functional plasticity of macrophages: in situ reprogramming of tumor-associated macrophages.

Authors:  Robert D Stout; Stephanie K Watkins; Jill Suttles
Journal:  J Leukoc Biol       Date:  2009-07-15       Impact factor: 4.962

10.  Enhancement of the anti-melanoma response of Hu14.18K322A by αCD40 + CpG.

Authors:  Kory L Alderson; Mitchell Luangrath; Megan M Elsenheimer; Stephen D Gillies; Fariba Navid; Alexander L Rakhmilevich; Paul M Sondel
Journal:  Cancer Immunol Immunother       Date:  2012-11-15       Impact factor: 6.968

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.